menu search

POLBF / Poolbeg Pharma consortium wins grant to develop oral vaccines

Poolbeg Pharma consortium wins grant to develop oral vaccines
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said its 'EncOVac' consortium has been awarded €2.3mln in grant funding to progress its oral vaccine platform under the Irish government's Disruptive Technologies Innovation Fund (DTIF). The consortium, a collaboration between Poolbeg, University College Dublin, Trinity College Dublin and AnaBio Technologies, plans to develop the oral vaccine candidate to a Phase-one ready state in three years. Read More
Posted: Nov 15 2022, 09:13
Author Name: Proactive Investors
Views: 103110

POLBF News  

Poolbeg's lead asset to be in the spotlight at leading medical conference

By Proactive Investors
November 3, 2023

Poolbeg's lead asset to be in the spotlight at leading medical conference

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said the potential of its lead asset will be discussed at a leading medical conference in December. A poste more_horizontal

Poolbeg investor meeting will take a deep dive into lead programme

By Proactive Investors
November 1, 2023

Poolbeg investor meeting will take a deep dive into lead programme

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin more_horizontal

Poolbeg advisory board endorses flu drug approach

By Proactive Investors
October 26, 2023

Poolbeg advisory board endorses flu drug approach

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has secured an endorsement from its scientific advisory board (SAB) of the prioritised targets for more_horizontal

Poolbeg Pharma up 8% on deal with Nasdaq biotech

By Proactive Investors
October 17, 2023

Poolbeg Pharma up 8% on deal with Nasdaq biotech

Shares in Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) rose 8% in early trading after the company announced a partnership with an unnamed Nasdaq-listed more_horizontal

Poolbeg Pharma inks collaboration agreement with Nasdaq biotech

By Proactive Investors
October 17, 2023

Poolbeg Pharma inks collaboration agreement with Nasdaq biotech

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has inked an agreement with an unnamed Nasdaq-listed biopharmaceutical entity aimed at developing more_horizontal

Poolbeg Pharma closes chapter on patent challenge

By Proactive Investors
September 29, 2023

Poolbeg Pharma closes chapter on patent challenge

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical group, has announced the cancellation of the European Patent Office ( more_horizontal

Poolbeg Pharma shores up protection around its IP

By Proactive Investors
September 20, 2023

Poolbeg Pharma shores up protection around its IP

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the clinical-stage biopharmaceutical firm, recently received a notice of allowance from the Japanese Paten more_horizontal

Poolbeg Pharma: Third party withdraws patent opposition

By Proactive Investors
September 19, 2023

Poolbeg Pharma: Third party withdraws patent opposition

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said that an unnamed 'third party' has agreed to withdraw its opposition to one of the company's European more_horizontal


Search within

Pages Search Results: